Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies

Afsaneh Alavi, Iltefat Hamzavi, Kurt Brown, Leandro L Santos, Zhaoyin Zhu, Huiqing Liu, Michael D Howell, Joslyn S Kirby, Afsaneh Alavi, Iltefat Hamzavi, Kurt Brown, Leandro L Santos, Zhaoyin Zhu, Huiqing Liu, Michael D Howell, Joslyn S Kirby

Abstract

Background: Janus kinase (JAK)-mediated cytokine signalling contributes to local and systemic inflammation in hidradenitis suppurativa (HS).

Objectives: To describe the safety and efficacy results from two multicentre phase II trials of the JAK1 inhibitor INCB054707 in patients with moderate-to-severe HS.

Methods: Patients received open-label INCB054707 15 mg once daily (QD; Study 1) or were randomized to INCB054707 30, 60 or 90 mg QD or placebo (3 : 1 within each cohort; Study 2) for 8 weeks. Eligible patients were aged 18-75 years and had moderate-to-severe HS (Hurley stage II/III disease), lesions present in at least two anatomical locations, and a total abscess and inflammatory nodule count ≥ 3. The primary endpoint for both studies was safety and tolerability. Secondary endpoints included HS Clinical Response (HiSCR) and other efficacy measures.

Results: Ten patients were enrolled in Study 1 (15 mg INCB054707) and 35 in Study 2 (INCB054707: 30 mg, n = 9; 60 mg, n = 9; 90 mg, n = 8; placebo, n = 9). Overall, 70% of patients in Study 1 and 81% of patients receiving INCB054707 in Study 2 experienced at least one treatment-emergent adverse event; 30% and 42% of patients, respectively, had at least one treatment-related adverse event. Among the evaluable patients, three (43%) in Study 1 and 17 (65% overall: 30 mg, 56%; 60 mg, 56%; 90 mg, 88%) receiving INCB054707 vs. 4 patients (57%) receiving placebo in Study 2 achieved HiSCR at week 8.

Conclusions: INCB054707 was well tolerated, with responses observed in patients with moderate-to-severe HS. The safety and efficacy findings from these studies demonstrate proof of concept for JAK1 inhibition in HS. The studies are registered on ClinicalTrials.gov (NCT03569371 and NCT03607487).

© 2022 Incyte Corporation. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Figures

Figure 1
Figure 1
Hidradenitis Suppurativa Clinical Response (HiSCR) by study visit. EOT, end of treatment. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
(a) Abscess and inflammatory nodule (AN) count 0–2. (b) Mean change from baseline in AN count. (c) Mean change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) by study visit. EOT, end of treatment. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 3
Figure 3
Mean changes from baseline in (a) Hidradenitis Suppurativa Quality of Life (HiSQoL), (b) worst skin pain and (c) Dermatology Life Quality Index (DLQI) by study visit. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 4
Figure 4
(a) Heat map from broad proteomic analysis showing fold change (FCH) from baseline in disease‐associated markers at weeks 4 and 8. Protein expression profiles of (b) tumour necrosis factor (TNF) and (c) interleukin‐2 receptor α (IL2RA). FDR, false discovery rate. *FDR wileyonlinelibrary.com]

References

    1. Vossen A, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol 2018; 9:2965.
    1. Scuderi N, Monfrecola A, Dessy LA et al. Medical and surgical treatment of hidradenitis suppurativa: a review. Skin Appendage Disord 2017; 3:95–110.
    1. Sabat R, Jemec GBE, Matusiak L et al. Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6:18.
    1. Nguyen TV, Damiani G, Orenstein LAV et al. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021; 35:50–61.
    1. Ingram JR, Jenkins‐Jones S, Knipe DW et al. Population‐based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol 2018; 178:917–24.
    1. Calao M, Wilson JL, Spelman L et al. Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population‐based cross‐sectional study. PLOS ONE 2018; 13:e0200683.
    1. Delany E, Gormley G, Hughes R et al. A cross‐sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venereol 2018; 32:467–73.
    1. Garg A, Kirby JS, Lavian J et al. Sex‐ and age‐adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 2017; 153:760–4.
    1. Hayama K, Fujita H, Hashimoto T et al. 026 Nationwide investigation of hidradenitis suppurativa in Japan. J Invest Dermatol 2017; 137 (Suppl. 2):S197.
    1. Cosmatos I, Matcho A, Weinstein R et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 68:412–19.
    1. Garg A, Wertenteil S, Baltz R et al. Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender‐ and age‐adjusted population analysis. J Invest Dermatol 2018; 138:2152–6.
    1. Vossen A, van der Zee HH, Onderdijk AJ et al. Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: a cross‐sectional study. J Dermatol 2017; 44:154–9.
    1. Garg A, Neuren E, Cha D et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol 2020; 82:366–76.
    1. Benhadou F, Van der Zee HH, Pascual JC et al. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross‐sectional study among 2465 patients. Br J Dermatol 2019; 181:1198–206.
    1. Peterson GC, Preston A, Frieder J et al. Analysis of characteristics and trends in treatment response of hidradenitis suppurativa patients: a Southern US cohort study. Dermatology 2020; 236:413–20.
    1. Jorgensen AR, Holm JG, Ghazanfar MN et al. Factors affecting quality of life in patients with hidradenitis suppurativa. Arch Dermatol Res 2020; 312:427–36.
    1. Mac Mahon J, Kirthi S, Byrne N et al. An update on health‐related quality of life and patient‐reported outcomes in hidradenitis suppurativa. Patient Relat Outcome Meas 2020; 11:21–6.
    1. Yao Y, Jorgensen AR, Thomsen SF. Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross‐sectional study. Int J Dermatol 2020; 59:333–40.
    1. Alavi A, Farzanfar D, Rogalska T et al. Quality of life and sexual health in patients with hidradenitis suppurativa. Int J Womens Dermatol 2018; 4:74–9.
    1. Koumaki D, Efthymiou O, Bozi E et al. Perspectives on perceived stigma and self‐stigma in patients with hidradenitis suppurativa. Clin Cosmet Investig Dermatol 2019; 12:785–90.
    1. Kimball AB, Crowley JJ, Papp K et al. Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. J Eur Acad Dermatol Venereol 2020; 34:1302–8.
    1. Kouris A, Platsidaki E, Christodoulou C et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology 2016; 232:687–91.
    1. Hamzavi IH, Sundaram M, Nicholson C et al. Uncovering burden disparity: a comparative analysis of the impact of moderate‐to‐severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol 2017; 77:1038–46.
    1. Savage KT, Flood KS, Porter ML et al. TNF‐α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis 2019; 10:2040622319851640.
    1. Kimball AB, Okun MM, Williams DA et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375:422–34.
    1. Frew JW, Jiang CS, Singh N et al. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. Clin Exp Dermatol 2021; 46:306–13.
    1. Welsch K, Holstein J, Laurence A et al. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 2017; 47:1096–107.
    1. Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol 2019; 10:2342.
    1. Witte‐Handel E, Wolk K, Tsaousi A et al. The IL‐1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol 2019; 139:1294–305.
    1. Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Res 2018; 7:1930.
    1. Jimenez‐Gallo D, de la Varga‐Martinez R, Ossorio‐Garcia L et al. The clinical significance of increased serum proinflammatory cytokines, C‐reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017; 2017:2450401.
    1. Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol 2019; 10:2847.
    1. Yang XO, Panopoulos AD, Nurieva R et al. STAT3 regulates cytokine‐mediated generation of inflammatory helper T cells. J Biol Chem 2007; 282:9358–63.
    1. Kelly G, Hughes R, McGarry T et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 2015; 173:1431–9.
    1. Liu T, Li S, Ying S et al. The IL‐23/IL‐17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol 2020; 11:594735.
    1. Schlapbach C, Hänni T, Yawalkar N et al. Expression of the IL‐23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65:790–8.
    1. Kelly G, Prens EP. Inflammatory mechanisms in hidradenitis suppurativa. Dermatol Clin 2016; 34:51–8.
    1. Savage KT, Santillan MR, Flood KS et al. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep 2020; 6:99–102.
    1. Fay B, He X, Margulis A et al. OP0280 The selective JAK1 inhibitor INCB054707 ameliorates cutaneous lesions in a spontaneous murine model of systemic lupus erythematosus. Ann Rheum Dis 2019; 78 (Suppl. 2):221–2.
    1. Schwartz DM, Bonelli M, Gadina M et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 2016; 12:25–36.
    1. Akada H, Akada S, Hutchison RE et al. Critical role of JAK2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells 2014; 32:1878–89.
    1. Zouboulis CC, Del Marmol V, Mrowietz U et al. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 2015; 231:184–90.
    1. Kimball AB, Sobell JM, Zouboulis CC et al. HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol 2016; 30:989–94.
    1. Zouboulis CC, Tzellos T, Kyrgidis A et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177:1401–9.
    1. Kirby JS, Thorlacius L, Villumsen B et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 2020; 183:340–8.
    1. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9:169–80.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57:289–300.
    1. Coates M, Mariottoni P, Corcoran DL et al. The skin transcriptome in hidradenitis suppurativa uncovers an antimicrobial and sweat gland gene signature which has distinct overlap with wounded skin. PLOS ONE 2019; 14:e0216249.
    1. Rumberger BE, Boarder EL, Owens SL et al. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm Res 2020; 69:967–73.
    1. Silverberg JI, Simpson EL, Thyssen JP et al. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156:863–73.
    1. Gooderham MJ, Forman SB, Bissonnette R et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 2019; 155:1371–9.
    1. Schmieder GJ, Draelos ZD, Pariser DM et al. Efficacy and safety of the Janus kinase 1 inhibitor PF‐04965842 in patients with moderate‐to‐severe psoriasis: phase II, randomized, double‐blind, placebo‐controlled study. Br J Dermatol 2018; 179:54–62.
    1. Simpson EL, Sinclair R, Forman S et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate‐to‐severe atopic dermatitis (JADE MONO‐1): a multicentre, double‐blind, randomised, placebo‐controlled, phase 3 trial. Lancet 2020; 396:255–66.
    1. Clarke B, Yates M, Adas M et al. The safety of JAK‐1 inhibitors. Rheumatology (Oxford) 2021; 60:ii24–ii30.
    1. Chang PH, Huang SF, Chang PS et al. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol 2021; 48:1631–9.
    1. Yates M, Mootoo A, Adas M et al. Venous thromboembolism risk with JAK inhibitors: a meta‐analysis. Arthritis Rheumatol 2021; 73:779–88.
    1. Zouboulis CC, Gulliver W, Ingram J et al. Endpoints of clinical trials for hidradenitis suppurativa: proceedings of a round‐table session. Exp Dermatol 2020; 29 (Suppl. 1):67–72.
    1. Frew JW, Jiang CS, Singh N et al. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data. J Am Acad Dermatol 2020; 82:1150–7.
    1. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor‐alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti‐tumour necrosis factor‐alpha agents? Acta Derm Venereol 2009; 89:601–3.
    1. Liao W, Lin JX, Leonard WJ. Interleukin‐2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13–25.
    1. Matusiak Ł, Bieniek A, Szepietowski JC. Soluble interleukin‐2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging. Biomarkers 2009; 14:432–7.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere